Bayer faces key Missouri court test of $7.25 billion Roundup deal

• Judge Timothy Boyer will evaluate the settlement and objections from some plaintiffs' attorneys who argue their clients shouldn't be forced into the proposed framework, though no immediate ruling is expected
• Settlement terms offer $10,000 to $165,000 based on cancer severity, age at diagnosis, and whether exposure occurred at home or work, aiming to resolve nearly all current and future U.S. Roundup claims
• Bayer recently won a Supreme Court ruling on Roundup's warning label adequacy while the settlement was pending, potentially weakening a key argument in plaintiffs' cases

Bayer Faces Missouri Court Test of $7.25 Billion Roundup Settlement

Key Facts:

Bayer's Monsanto unit is seeking Missouri state court approval for a $7.25 billion settlement to resolve approximately 65,000 U.S. lawsuits alleging its Roundup weedkiller causes cancer. Judge Timothy Boyer began hearing arguments on Monday in St. Louis, though no immediate ruling is expected.

Settlement Details:

The proposed deal, announced in February, aims to resolve nearly all current and future Roundup claims in the U.S. Payouts range from $10,000 to $165,000 for plaintiffs who developed non-Hodgkin lymphoma after Roundup exposure. Award amounts will depend on cancer severity, age at diagnosis, and whether exposure occurred at home or work.

Legal Background:

The litigation has plagued Bayer since its 2018 Monsanto acquisition, costing billions and weighing on its stock price. The controversy intensified after the WHO's International Agency for Research on Cancer classified glyphosate (Roundup's key ingredient) as a probable carcinogen in 2015. However, the U.S. EPA concluded in 2017 that glyphosate is not likely carcinogenic under normal exposure conditions.

Current Status:

Bayer recently gained ground when the Supreme Court sided with the company on warning label adequacy while the settlement was pending, undermining a key plaintiff argument. The company denies all claims, citing decades of safety studies.

Opposition:

Some plaintiffs' attorneys object to the settlement framework, arguing it offers insufficient compensation and forces claimants into a deal when they could pursue litigation, particularly concerning future plaintiffs who haven't yet developed cancer.

The EPA expects to complete an updated glyphosate health risk assessment by late 2026.